NEW YORK (GenomeWeb) – Cancer Genetics has reached a deal with Cantor Fitzgerald to sell up to $20 million of its common shares from time to time. 

The firm also said that its cash burn rate for the second quarter is anticipated to reach $4.8 million. 

In documents filed with the US Securities and Exchange Commission on Wednesday, Cancer Genetics said that the investment bank may sell shares deemed through an "at-the-market" offering, in which shares are offered at the prevailing market prices, or through other methods, including in privately negotiated transactions. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.